|
|
Article: With Antegren Launch Expected, Biogen Idec Tops 2Q Estimates.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Senior Staff Writer
Biogen Idec Inc. beat second-quarter earnings estimates.
For the period ended June 30, the Cambridge, Mass.-based firm posted earnings per share of 34 cents on an adjusted pro-forma basis. The consensus forecast called for earnings per share of 32 cents. In the year-earlier period, the company posted earnings per share of 29 cents.
Management expects full-year earnings per share to range between $1.34 and $1.55, on an adjusted basis.
"The last few months certainly have been an exciting time for the organization as we work toward commercializing Antegren," Biogen Idec CEO James Mullen said during a conference call. ...